Vitrolife AB (publ)
Vitrolife AB (publ) (VTRLY) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Vitrolife AB (publ) (VTRLY), featuring income statements, balance sheets, and cash flow data.
Vitrolife AB (publ) (VTRLY) Income Statement & Financial Overview
Analyze Vitrolife AB (publ)’s VTRLY earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $842.00M | $959.00M | $867.00M | $941.00M |
| Cost of Revenue | $359.00M | $373.00M | $359.00M | $442.00M |
| Gross Profit | $483.00M | $586.00M | $508.00M | $499.00M |
| Gross Profit Ratio | $0.57 | $0.61 | $0.59 | $0.53 |
| R&D Expenses | $26.00M | $28.00M | $30.00M | $26.00M |
| SG&A Expenses | $298.00M | $341.00M | $290.00M | $314.00M |
| Operating Expenses | $332.00M | $361.00M | $334.00M | $261.00M |
| Total Costs & Expenses | $691.00M | $734.00M | $693.00M | $703.00M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $18.00M | $25.00M |
| Depreciation & Amortization | $106.00M | $0.00 | -$1.00M | $109.00M |
| EBITDA | $256.00M | $225.00M | $173.00M | $326.00M |
| EBITDA Ratio | $0.30 | $0.23 | $0.20 | $0.35 |
| Operating Income | $151.00M | $225.00M | $174.00M | $238.00M |
| Operating Income Ratio | $0.18 | $0.23 | $0.20 | $0.25 |
| Other Income/Expenses (Net) | -$10.00M | -$43.00M | -$18.00M | -$26.00M |
| Income Before Tax | $141.00M | $182.00M | $156.00M | $192.00M |
| Income Before Tax Ratio | $0.17 | $0.19 | $0.18 | $0.20 |
| Income Tax Expense | $41.00M | $43.00M | $40.00M | $49.00M |
| Net Income | $100.00M | $139.00M | $116.00M | $143.00M |
| Net Income Ratio | $0.12 | $0.14 | $0.13 | $0.15 |
| EPS | $0.74 | $1.03 | $0.86 | $1.06 |
| Diluted EPS | $0.74 | $1.02 | $0.86 | $1.06 |
| Weighted Avg Shares Outstanding | $135.42M | $135.42M | $135.42M | $135.40M |
| Weighted Avg Shares Outstanding (Diluted) | $135.42M | $135.57M | $135.57M | $135.40M |
The company's financials show resilient growth, with revenue advancing from $941.00M in Q2 2024 to $842.00M in Q1 2025. Gross profit remained healthy with margins at 57% in Q1 2025 compared to 53% in Q2 2024. Operating income hit $151.00M last quarter, sustaining a consistent 18% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $256.00M. Net income dropped to $100.00M, while earnings per share reached $0.74. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan